Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.

Sonpavde GP, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, Crabb SJ, Bellmunt J, Yu EY, Niegisch G, Vaishampayan UN, Theodore C, Berthold DR, Srinivas S, Sridhar SS, Plimack ER, Rosenberg JE, Powles T, Galsky MD, Necchi A.

J Urol. 2018 Dec;200(6):1207-1214. doi: 10.1016/j.juro.2018.07.035. Epub 2018 Sep 4.

PMID:
30012366
2.

Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L; RISC Investigators.

Eur Urol. 2017 Feb;71(2):281-289. doi: 10.1016/j.eururo.2016.09.042. Epub 2016 Oct 8.

3.

Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.

Moschini M, Shariat SF, Rouprêt M, De Santis M, Bellmunt J, Sternberg CN, Tombal B, Collette L.

J Urol. 2018 May;199(5):1149-1157. doi: 10.1016/j.juro.2017.11.068. Epub 2017 Nov 20.

PMID:
29158104
4.

Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study.

Rozzi A, Salerno M, Bordin F, De Marco F, Di Nicola S, Lanzetta G.

Med Oncol. 2011 Dec;28 Suppl 1:S426-32. doi: 10.1007/s12032-010-9749-z. Epub 2010 Nov 30.

PMID:
21116878
5.

Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study.

Nakagawa T, Komemushi Y, Kawai T, Otsuka M, Miyakawa J, Uemura Y, Kanatani A, Taguchi S, Naito A, Suzuki M, Nishimatsu H, Hirano Y, Tanaka Y, Matsumoto A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y.

World J Urol. 2017 Oct;35(10):1569-1575. doi: 10.1007/s00345-017-2032-6. Epub 2017 Apr 10.

PMID:
28397000
6.

Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma.

Hurwitz ME, Markowski P, Yao X, Deshpande H, Patel J, Mortazavi A, Donadio A, Stein MN, Kelly WK, Petrylak DP, Mehnert JM.

Clin Genitourin Cancer. 2018 Dec;16(6):437-444.e6. doi: 10.1016/j.clgc.2018.07.021. Epub 2018 Jul 29.

PMID:
30177237
7.

The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.

Giannatempo P, Pond GR, Sonpavde G, Raggi D, Naik G, Galsky MD, Bellmunt J, Necchi A.

Eur Urol. 2016 Apr;69(4):624-633. doi: 10.1016/j.eururo.2015.09.051. Epub 2015 Oct 21. Review.

PMID:
26497923
8.
9.

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J.

Lancet Oncol. 2017 Nov;18(11):1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26.

PMID:
28967485
10.

Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.

García-Donas J, Font A, Pérez-Valderrama B, Virizuela JA, Climent MÁ, Hernando-Polo S, Arranz JÁ, Del Mar Llorente M, Lainez N, Villa-Guzmán JC, Mellado B, González Del Alba A, Castellano D, Gallardo E, Anido U, García Del Muro X, Domènech M, Puente J, Morales-Barrera R, Pérez-Gracia JL, Bellmunt J.

Lancet Oncol. 2017 May;18(5):672-681a. doi: 10.1016/S1470-2045(17)30242-5. Epub 2017 Apr 4. Erratum in: Lancet Oncol. 2019 Jan;20(1):e9.

PMID:
28389316
11.

Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.

Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF.

Clin Genitourin Cancer. 2011 Sep;9(1):27-30. doi: 10.1016/j.clgc.2011.05.003. Epub 2011 Jun 22.

PMID:
21700509
12.

Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.

Fukushima H, Kataoka M, Nakanishi Y, Sakamoto K, Takemura K, Suzuki H, Ito M, Tobisu KI, Fujii Y, Koga F.

Urol Oncol. 2018 Apr;36(4):156.e9-156.e16. doi: 10.1016/j.urolonc.2017.09.016. Epub 2017 Oct 17.

PMID:
29051030
13.

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.

Ning YM, Suzman D, Maher VE, Zhang L, Tang S, Ricks T, Palmby T, Fu W, Liu Q, Goldberg KB, Kim G, Pazdur R.

Oncologist. 2017 Jun;22(6):743-749. doi: 10.1634/theoncologist.2017-0087. Epub 2017 Apr 19.

14.

Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: a comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract.

Song YS, Cho JS, Cho KS, Doo SH, Chung BH, Kim SJ, Yang WJ, Song KH, Kim CI, Hong SJ.

Urol Int. 2010;85(1):47-51. doi: 10.1159/000296294. Epub 2010 Mar 16.

PMID:
20234122
15.

Safety of Vinflunine in Patients with Advanced Urothelial Carcinoma Refractory to Platinum-based Chemotherapy: A Prospective Pilot Study.

Abdel-Malek R, Shohdy KS, Abbas N, Ismail M, Hamada E, Abdel-Kader Y.

Curr Drug Saf. 2019;14(1):31-36. doi: 10.2174/1574886313666181001120752.

PMID:
30277164
16.

Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.

Rossi A, Chiodini P, Sun JM, O'Brien ME, von Plessen C, Barata F, Park K, Popat S, Bergman B, Parente B, Gallo C, Gridelli C, Perrone F, Di Maio M.

Lancet Oncol. 2014 Oct;15(11):1254-62. doi: 10.1016/S1470-2045(14)70402-4. Epub 2014 Sep 14. Review.

PMID:
25232001
17.

Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).

Passalacqua R, Lazzarelli S, Donini M, Montironi R, Tambaro R, De Giorgi U, Pignata S, Palumbo R, Ceresoli GL, Del Conte G, Tonini G, Morelli F, Nolè F, Panni S, Rondini E, Guida A, Zucali PA, Doni L, Iezzi E, Caminiti C.

BMC Cancer. 2017 Jul 19;17(1):493. doi: 10.1186/s12885-017-3466-3.

18.

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.

Pal SK, Hoffman-Censits J, Zheng H, Kaiser C, Tayama D, Bellmunt J.

Eur Urol. 2018 May;73(5):800-806. doi: 10.1016/j.eururo.2018.02.010. Epub 2018 Feb 22.

PMID:
29478735
19.

[Combination therapy consisting of gemcitabine, docetaxel and carboplatin as a second-line chemotherapy for patients with MVAC-treated metastatic urothelial carcinoma].

Inoue T, Obara T, Saito M, Kumazawa T, Narita S, Horikawa Y, Yuasa T, Tsuchiya N, Satoh S, Habuchi T.

Hinyokika Kiyo. 2008 Sep;54(9):581-5. Japanese.

20.

Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.

Ardavanis A, Tryfonopoulos D, Alexopoulos A, Kandylis C, Lainakis G, Rigatos G.

Br J Cancer. 2005 Feb 28;92(4):645-50.

Supplemental Content

Support Center